Cite

HARVARD Citation

    Wechsler, M. et al. (2022). Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet. 10 (1), pp. 11-25. [Online]. 
  
Back to record